Clinical trial
Oral Enzastaurin in Participants With Relapsed Mantle Cell Lymphoma
NCT00088205 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00088205 |
|---|---|
| Title | Oral Enzastaurin in Participants With Relapsed Mantle Cell Lymphoma |
| Official title | A Phase 2 Study of Oral Enzastaurin HCl in Patients With Relapsed Mantle Cell Lymphoma |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Mantle-Cell Lymphoma |
| Intervention type | Drug |
| Interventions | enzastaurin |
| Enrollment | 60 |
| Start date | Mar 1, 2004 |
| Primary completion | May 1, 2008 |
| Completion | May 1, 2008 |
| First posted | Jul 23, 2004 |
| Last update posted | Jul 1, 2020 |
| Countries | Australia, France, Germany, Netherlands |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: